Atonco

Executive Summary

Atonco is a clinical-stage French radiopharmaceutical company pioneering targeted alpha-immunotherapy using the radionuclide Astatine-211. Founded in 2019, the company aims to eradicate residual microscopic disease after conventional cancer treatments, thereby improving patients' survival and quality of life. Its approach leverages the short-range, high-energy alpha particles of Astatine-211 to selectively destroy cancer cells while sparing healthy tissues, addressing key limitations of existing therapies. The initial pipeline focuses on rapidly accessible tumor types that are well-suited to the physical properties of alpha particles, positioning Atonco as a potential leader in the emerging field of targeted alpha therapy. Currently in Phase 1 clinical development, Atonco has yet to disclose specific pipeline candidates publicly but emphasizes a strategy of targeting accessible tumors to accelerate clinical validation. The company benefits from France's supportive biotech ecosystem and growing interest in radiopharmaceuticals. While still early-stage, Atonco's differentiated technology and clear unmet need provide a compelling investment thesis. The next 12–18 months should reveal initial clinical data and strategic partnerships that will be critical for valuation inflection. Conviction is moderate given the early stage and lack of disclosed pipeline details, but the therapeutic potential is significant.

Upcoming Catalysts (preview)

• H1 2027Initial Phase 1 clinical data readout for lead Astatine-211 candidate50% success
• Q3 2026Orphan Drug Designation from EMA or FDA for lead indication70% success
• H2 2026Strategic partnership for Astatine-211 supply chain or co-development40% success